Management of Porphyria Cutanea Tarda Manifestations

Clinical Manifestations and Management

The standard of care for managing porphyria cutanea tarda (PCT) manifestations includes photo-protection, therapeutic phlebotomy to reduce hepatic iron stores, and low-dose antimalarial drugs such as chloroquine, as recommended by the American Autoimmunity Association 1, 2
Typical cutaneous lesions in sun-exposed areas, particularly on the hands and face, are a common manifestation of PCT 3, 4
Photosensitivity requiring strict sun avoidance and protection is a key aspect of PCT management 1
Skin fragility leading to blisters and erosions, as well as facial hypertrichosis (excessive hair growth), are also characteristic of PCT 3, 4
Late-stage sclerodermoid plaques can occur in PCT patients 3

Therapeutic phlebotomy is the primary treatment to reduce hepatic iron stores, a critical pathogenetic factor in PCT, as recommended by the American Autoimmunity Association 1, 2
Low-dose antimalarial therapy, such as chloroquine, helps eliminate porphyrins and is particularly useful when phlebotomy is contraindicated or poorly tolerated 1

Treatment of hepatitis C virus (HCV) infection, if present, is essential in PCT management, with direct-acting antivirals (DAAs) without interferon or ribavirin being preferred, as recommended by the American Autoimmunity Association 1, 3
Alcohol cessation is critical as it is a common trigger for PCT 3
Avoidance of other triggering factors, such as estrogens, liver toxins, and medications that can exacerbate PCT, is also important 3

Biochemical monitoring of urinary porphyrin levels should guide treatment duration, as recommended by the Praxis Medical Insights 2
Samples for porphyrin testing should be protected from light to avoid falsely low results, as recommended by the Praxis Medical Insights 2

Regular phlebotomies should be performed until iron stores are depleted, followed by maintenance therapy guided by serum ferritin levels, as recommended by the American Association for the Study of Liver Diseases 5
Patients with cirrhosis should undergo regular screening for hepatocellular carcinoma, as part of their management plan 5
Iron supplementation and vitamin C supplements should be avoided in patients with porphyria cutanea tarda, to prevent exacerbation of the disease 5